{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:38:11Z","timestamp":1753871891443,"version":"3.41.2"},"reference-count":21,"publisher":"Portland Press Ltd.","issue":"4","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":161,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ovarian cancer is one of the most common gynecological cancers with a high mortality rate in females. Chromatin target of protein arginine methyltransferase (CHTOP) is an important intracellular protein that regulates the transcriptional activation of several oncogenic genes in glioblastomagenesis and controls mature mRNA export as a component of TRanscription-Export complex. However, the role of CHTOP in ovarian cancer is unclear. In the present study, we investigated the correlation between tumor-derived CHTOP expression and prognosis and explored its role in the malignant behaviors of epithelial ovarian cancer cells. We found that higher expression of CHTOP was associated with a lower disease-free survival (DFS) rate in ovarian cancer patients. Also, CHTOP was highly expressed in human ovarian cancer tissues compared with normal and adjacent tissues. Moreover, compared with IGROV-1 cell line, higher expression of CHTOP was also confirmed in the malignant ovarian cancer cell lines (OV-90 and SK-OV-3). Further results from wound-healing and Matrigel assay showed that CHTOP knockdown significantly reduced the migration and invasion ability of OV-90 and SK-OV-3 cells, while colony formation assay and apoptosis detection showed that CHTOP knockdown markedly sensitized OV-90 and SK-OV-3 cells to cisplatin treatment by inducing apoptosis. Additionally, CHTOP silence also remarkably weakened the stemness of OV-90 and SK-OV-3 through inhibiting the protein expressions of several transcriptional or surface markers of cancer stem cells. These findings first suggest that CHTOP, as a highly expressed protein in ovarian cancer, is closely associated with the malignant phenotypes of epithelial ovarian cancer cells, including metastasis, chemoresistance, and stemness, which highlights a promising role of CHTOP in ovarian cancer targeted therapy.<\/jats:p>","DOI":"10.1042\/bsr20190016","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T17:45:46Z","timestamp":1553535946000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chromatin target of protein arginine methyltransferase regulates invasion, chemoresistance, and stemness in epithelial ovarian cancer"],"prefix":"10.1042","volume":"39","author":[{"given":"Xiaojie","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suxia","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5393-1405","authenticated-orcid":false,"given":"Xupeng","family":"Bai","sequence":"additional","affiliation":[{"name":"Cancer Care Centre, St George Hospital, Kogarah, New South Wales, Australia"},{"name":"St George and Sutherland Clinical School, Faculty of Medicine, UNSW Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"2021111619273206400_B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"2021111619273206400_B2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","article-title":"Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations","volume":"204","author":"Salani","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"2021111619273206400_B3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","article-title":"An international assessment of ovarian cancer incidence and mortality","volume":"130","author":"Lowe","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"2021111619273206400_B4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"Agarwal","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"2021111619273206400_B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7150\/jca.7810","article-title":"Current approaches and challenges in managing and monitoring treatment response in ovarian cancer","volume":"5","author":"Marcus","year":"2014","journal-title":"J. Cancer"},{"key":"2021111619273206400_B6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1128\/MCB.00645-09","article-title":"Friend of Prmt1, a novel chromatin target of protein arginine methyltransferases","volume":"30","author":"van Dijk","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"2021111619273206400_B7","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/blood-2010-03-274399","article-title":"Fetal globin expression is regulated by Friend of Prmt1","volume":"116","author":"van Dijk","year":"2010","journal-title":"Blood"},{"key":"2021111619273206400_B8","doi-asserted-by":"publisher","first-page":"e67676","DOI":"10.1371\/journal.pone.0067676","article-title":"Mapping interactions between mRNA export factors in living cells","volume":"8","author":"Teng","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111619273206400_B9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.celrep.2014.08.071","article-title":"5-Hydroxymethylcytosine plays a critical role in glioblastomagenesis by recruiting the CHTOP-methylosome complex","volume":"9","author":"Takai","year":"2014","journal-title":"Cell Rep."},{"key":"2021111619273206400_B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/ERC-11-0329","article-title":"Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients","volume":"19","author":"Gyorffy","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"2021111619273206400_B11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1470-2045(05)01742-0","article-title":"Intramedullary spinal metastasis from ovarian cancer","volume":"6","author":"Rastelli","year":"2005","journal-title":"Lancet Oncol."},{"key":"2021111619273206400_B12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1159\/000487348","article-title":"Downregulation of SPINK13 promotes metastasis by regulating uPA in ovarian cancer cells","volume":"45","author":"Cai","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"2021111619273206400_B13","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(06)68671-6","article-title":"Surgery for ovarian cancer: how to improve survival","volume":"367","author":"Bristow","year":"2006","journal-title":"Lancet"},{"key":"2021111619273206400_B14","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1038\/onc.2011.539","article-title":"A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer","volume":"31","author":"Ratner","year":"2012","journal-title":"Oncogene"},{"key":"2021111619273206400_B15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2021111619273206400_B16","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"2021111619273206400_B17","doi-asserted-by":"publisher","first-page":"417","DOI":"10.4161\/cc.23275","article-title":"Vitamin B6 metabolism influences the intracellular accumulation of cisplatin","volume":"12","author":"Galluzzi","year":"2013","journal-title":"Cell Cycle"},{"key":"2021111619273206400_B18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/03602532.2016.1197239","article-title":"Emerging role of NRF2 in chemoresistance by regulating drug-metabolizing enzymes and efflux transporters","volume":"48","author":"Bai","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"2021111619273206400_B19","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1158\/0008-5472.CAN-17-0054","article-title":"New advances and challenges of targeting cancer stem cells","volume":"77","author":"Dashzeveg","year":"2017","journal-title":"Cancer Res."},{"key":"2021111619273206400_B20","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ctrv.2018.07.004","article-title":"Cancer stem cell in breast cancer therapeutic resistance","volume":"69","author":"Bai","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"2021111619273206400_B21","doi-asserted-by":"publisher","first-page":"E8948","DOI":"10.1073\/pnas.1806219115","article-title":"Expansion of cancer stem cell pool initiates lung cancer recurrence before angiogenesis","volume":"115","author":"Li","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20190016\/842604\/bsr-2019-0016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20190016\/842604\/bsr-2019-0016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:20:14Z","timestamp":1637094014000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/39\/4\/BSR20190016\/110865\/Chromatin-target-of-protein-arginine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20190016","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"type":"print","value":"0144-8463"},{"type":"electronic","value":"1573-4935"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,4]]},"article-number":"BSR20190016"}}